Aclidinium Bromide Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition:   Pulmonary Disease, Chronic Obstructive Intervention:   Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition:   Pulmonary Disease, Chronic Obstructive Intervention:   Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition:   Pulmonary Disease, Chronic Obstructive Intervention:   Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition:   Pulmonary Disease, Chronic Obstructive Intervention:   Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition:   Pulmonary Disease, Chronic Obstructive Intervention:   Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor:   AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials

An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified September 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials